Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206

Novan, Inc. today announced that the first patient has been dosed in the Company’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus. There is currently no FDA-approved treatment for the molluscum indication.